800 results on '"Benedet, Andrea"'
Search Results
2. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
3. CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
4. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
5. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
6. Vascular risk burden is a key player in the early progression of Alzheimer’s disease
7. 14-3-3 ζ/δ-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
8. A multicentre validation study of the diagnostic value of plasma neurofilament light.
9. Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies
10. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
11. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
12. Staging of Alzheimer’s disease: past, present, and future perspectives
13. Acute sleep loss increases CNS health biomarkers and compromises the ability to stay awake in a sex-and weight-specific manner
14. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
15. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
16. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
17. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
18. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
19. APOEε4 potentiates the relationship between amyloid-β and tau pathologies
20. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
21. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
22. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease.
23. Microglial activation and tau propagate jointly across Braak stages
24. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
25. Sex modulates the role of astrocyte reactivity in preclinical Alzheimer’s disease
26. Synaptic dysfunction, Tau pathology and Neurodegeneration
27. Plasma pTau217: single vs multiple phospho‐site assays.
28. CSF total tau is more closely associated with synaptic dysfunction than overt neurodegeneration
29. Blood‐based SNAP‐25 and VAMP‐2 in Alzheimer’s disease; relation to cognition, atrophy and synaptic density.
30. Association of reactive astrogliosis and microglial activation with tau pathology in Alzheimer’s disease
31. Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum
32. Plasma p‐tau and brain‐derived total tau biomarkers predict longitudinal changes in Aβ, tau, and cognition across the AD continuum
33. Neuroinflammation Exacerbates Irritability and Agitation in Alzheimer’s Disease
34. Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer’s disease
35. Associations and interactions of synaptic and inflammatory biomarkers in Alzheimer's disease
36. Plasma biomarkers as stand‐alone tests in the diagnosis of Alzheimer’s disease
37. Association between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
38. APOEε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation
39. Interactions of synaptic and inflammatory biomarkers in Alzheimer’s Disease
40. Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes
41. Fast accumulators of tau have higher levels of plasma pTau and stronger associations with amyloid in later Braak regions at baseline
42. Association between brain [18F]FDG‐PET signal and genetic cell markers in the brain tissue
43. The impact of young controls in the detection of tau load in cognitively impaired and asymptomatic elderly
44. Plasma p-tau 181 outperforms FDG-PET in the early diagnosis of biological AD
45. Plasma biomarkers rates of change across the preclinical stage of Alzheimer’s disease: a longitudinal study
46. Microglial activation interacts with amyloid‐β to drive longitudinal tau tangle accumulation and cognitive decline
47. Clinical proteomic analysis across the Alzheimer’s disease continuum
48. Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction related to cognitive impairment
49. Potential utility of using both APOEε4 and Aβ positivity to enrich clinical trials of tau‐targeting therapies
50. Sex impacts the association of plasma Glial Fibrillary Acidic Protein with neurodegeneration in Alzheimer’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.